Fibrin Monomer in Thrombosis and Haemostasis: A Clinical Biomarker and Beyond
International Journal of Molecular Sciences · 07.12.2025 · 26 (24) · 11822
DOI: 10.3390/ijms262411822 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.12.2025. Verfasst von Konstantin Guria und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Research Centre of Cardiology Named After Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A Akademika Chazo…. Hauptthemen laut MEDLINE: Hemostasis, Thrombosis, Fibrin Fibrinogen Degradation Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Russian Science Foundation.
Abstract (Originalsprache)
Fibrin monomer (FM) is a transient intermediate of blood coagulation that functions as both an active regulator of haemostasis and a sensitive biomarker for prothrombotic states. Clinically, FM is measured indirectly as its derivative, soluble fibrin monomer complexes (SFMC), which is also often referred to as FM throughout the clinical literature. FM participates in a complex regulatory network modulating thrombin generation and fibrinolysis, interacting with platelet receptors, including integrin αIIbβ3 and GPVI, and engaging GPIb-vWF interactions. This comprehensive review examines FM’s molecular mechanisms in haemostatic regulation and evaluates clinical evidence for FM as a biomarker. Particular focus is placed on FM’s utility for risk stratification across thrombotic conditions, including disseminated intravascular coagulation, venous thromboembolism, ischemic stroke, myocardial infarction, and COVID-19-associated coagulopathy. Current challenges, including assay standardization and universal cut-off values, are discussed. By synthesizing mechanistic insights with clinical data, this integrated perspective may accelerate the translation of FM biology into improved risk assessment tools and novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Medical Research Centre of Cardiology Named After Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A Akademika Chazova Street, 121552 Moscow, Russia.
- State Research Center of the Russian Federation, Institute of Biomedical Problems of Russian Academy of Sciences, 76A Khoroshevskoye Shosse, 123007 Moscow, Russia.
ORCID-Profile: Konstantin Guria, Ivan Melnikov, Valentina Shtelmakh, Yuliya Avtaeva, Sergey Okhota, Sergey Kozlov, Zufar Gabbasov
Förderung
- the Russian Science Foundation
Zitieren
APA
Guria, K., Melnikov, I., Shtelmakh, V., Avtaeva, Y., Okhota, S., Saburova, O., Kozlov, S., & Gabbasov, Z. (2025). Fibrin Monomer in Thrombosis and Haemostasis: A Clinical Biomarker and Beyond. International Journal of Molecular Sciences, 26(24), 11822. https://doi.org/10.3390/ijms262411822
Vancouver
Guria K, Melnikov I, Shtelmakh V, Avtaeva Y, Okhota S, Saburova O, et al. Fibrin Monomer in Thrombosis and Haemostasis: A Clinical Biomarker and Beyond. International Journal of Molecular Sciences. 2025;26(24):11822. doi:10.3390/ijms262411822
BibTeX
@article{Guria2025,
author = {Guria, Konstantin and Melnikov, Ivan and Shtelmakh, Valentina and Avtaeva, Yuliya and Okhota, Sergey and Saburova, Olga and Kozlov, Sergey and Gabbasov, Zufar},
title = {Fibrin Monomer in Thrombosis and Haemostasis: A Clinical Biomarker and Beyond},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {24},
pages = {11822},
doi = {10.3390/ijms262411822}
}
EUVIMED